08:00 , Dec 3, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes ELOVL family member 6 elongation of long-chain fatty acids (ELOVL6; FAE) In vitro and mouse studies identified benzoxazinone-based ELOVL6 inhibitors that could help...
07:00 , Jul 9, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Type 2 diabetes; obesity ELOVL family member 6, elongation of long-chain fatty acids (ELOVL6) In vitro and rodent studies identified an ELOVL6 inhibitor that...
07:00 , Oct 8, 2007 |  BioCentury  |  Strategy

Opportunistic transformation

Two and a half years ago, the management team at Evotec AG decided that a hybrid services/drug development model didn't work and opted to become a pure-play CNS company. The first signal of the transition...
07:00 , Jun 25, 2007 |  BC Week In Review  |  Company News

Inspire, Faes deal

FAE and ISPH amended a 2006 deal that granted ISPH exclusive U.S. and Canadian rights to commercialize and develop oral bilastine to treat allergic rhinitis (see BioCentury, Nov. 6, 2006). FAE is now responsible for...
08:00 , Nov 6, 2006 |  BC Week In Review  |  Company News

Inspire, Faes deal

FAE granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize oral bilastine to treat or prevent rhinitis, as well as an exclusive license to the ocular formulation in various markets...
08:00 , Nov 6, 2006 |  BioCentury  |  Strategy

A shelf full of antihistamines

With its newly licensed oral histamine H1 receptor antagonist, Inspire Pharmaceuticals Inc. thinks it can cover the delivery preferences of patients in the crowded allergy space. Inspire (ISPH, Durham, N.C.) last week obtained U.S. and...
00:52 , Nov 2, 2006 |  BC Extra  |  Company News

Inspire licenses Faes' bilastine

Faes (IBEX:FAE) granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize oral bilastine to treat or prevent rhinitis, as well as an exclusive license to the ocular formulation in various...